|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IWS1 |
Gene summary for IWS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IWS1 | Gene ID | 55677 |
| Gene name | interacts with SUPT6H, CTD assembly factor 1 | |
| Gene Alias | IWS1 | |
| Cytomap | 2q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000414 | UniProtAcc | Q96ST2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55677 | IWS1 | CCI_1 | Human | Cervix | CC | 5.24e-03 | 5.04e-01 | 0.528 |
| 55677 | IWS1 | CCI_2 | Human | Cervix | CC | 3.61e-02 | 4.80e-01 | 0.5249 |
| 55677 | IWS1 | CCI_3 | Human | Cervix | CC | 3.09e-03 | 5.18e-01 | 0.516 |
| 55677 | IWS1 | LZE4T | Human | Esophagus | ESCC | 2.53e-12 | 3.51e-01 | 0.0811 |
| 55677 | IWS1 | LZE5T | Human | Esophagus | ESCC | 3.01e-08 | 3.75e-01 | 0.0514 |
| 55677 | IWS1 | LZE7T | Human | Esophagus | ESCC | 2.01e-11 | 4.77e-01 | 0.0667 |
| 55677 | IWS1 | LZE8T | Human | Esophagus | ESCC | 1.54e-09 | 1.71e-01 | 0.067 |
| 55677 | IWS1 | LZE20T | Human | Esophagus | ESCC | 4.34e-12 | 1.56e-01 | 0.0662 |
| 55677 | IWS1 | LZE22T | Human | Esophagus | ESCC | 8.37e-09 | 4.00e-01 | 0.068 |
| 55677 | IWS1 | LZE24T | Human | Esophagus | ESCC | 3.80e-12 | 3.29e-01 | 0.0596 |
| 55677 | IWS1 | P1T-E | Human | Esophagus | ESCC | 1.68e-14 | 4.70e-01 | 0.0875 |
| 55677 | IWS1 | P2T-E | Human | Esophagus | ESCC | 7.11e-29 | 4.64e-01 | 0.1177 |
| 55677 | IWS1 | P4T-E | Human | Esophagus | ESCC | 9.26e-29 | 6.79e-01 | 0.1323 |
| 55677 | IWS1 | P5T-E | Human | Esophagus | ESCC | 1.07e-28 | 5.30e-01 | 0.1327 |
| 55677 | IWS1 | P8T-E | Human | Esophagus | ESCC | 6.78e-19 | 3.23e-01 | 0.0889 |
| 55677 | IWS1 | P9T-E | Human | Esophagus | ESCC | 9.99e-23 | 3.80e-01 | 0.1131 |
| 55677 | IWS1 | P10T-E | Human | Esophagus | ESCC | 1.16e-29 | 6.15e-01 | 0.116 |
| 55677 | IWS1 | P11T-E | Human | Esophagus | ESCC | 3.73e-13 | 4.58e-01 | 0.1426 |
| 55677 | IWS1 | P12T-E | Human | Esophagus | ESCC | 4.43e-35 | 6.94e-01 | 0.1122 |
| 55677 | IWS1 | P15T-E | Human | Esophagus | ESCC | 1.97e-26 | 6.07e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00069139 | Cervix | CC | nucleocytoplasmic transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:00511699 | Cervix | CC | nuclear transport | 71/2311 | 301/18723 | 4.04e-08 | 2.54e-06 | 71 |
| GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
| GO:00468229 | Cervix | CC | regulation of nucleocytoplasmic transport | 31/2311 | 106/18723 | 2.68e-06 | 7.87e-05 | 31 |
| GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
| GO:00511689 | Cervix | CC | nuclear export | 38/2311 | 154/18723 | 1.86e-05 | 3.46e-04 | 38 |
| GO:00512368 | Cervix | CC | establishment of RNA localization | 39/2311 | 166/18723 | 4.76e-05 | 7.25e-04 | 39 |
| GO:00506578 | Cervix | CC | nucleic acid transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
| GO:00506588 | Cervix | CC | RNA transport | 38/2311 | 163/18723 | 7.06e-05 | 9.85e-04 | 38 |
| GO:00506849 | Cervix | CC | regulation of mRNA processing | 33/2311 | 137/18723 | 1.06e-04 | 1.35e-03 | 33 |
| GO:00104525 | Cervix | CC | histone H3-K36 methylation | 8/2311 | 15/18723 | 1.53e-04 | 1.85e-03 | 8 |
| GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
| GO:000640310 | Cervix | CC | RNA localization | 43/2311 | 201/18723 | 2.00e-04 | 2.29e-03 | 43 |
| GO:00510284 | Cervix | CC | mRNA transport | 31/2311 | 130/18723 | 2.05e-04 | 2.33e-03 | 31 |
| GO:00349685 | Cervix | CC | histone lysine methylation | 27/2311 | 115/18723 | 6.61e-04 | 6.09e-03 | 27 |
| GO:00310565 | Cervix | CC | regulation of histone modification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
| GO:000838010 | Cervix | CC | RNA splicing | 76/2311 | 434/18723 | 9.79e-04 | 8.19e-03 | 76 |
| GO:00159318 | Cervix | CC | nucleobase-containing compound transport | 43/2311 | 222/18723 | 1.72e-03 | 1.30e-02 | 43 |
| GO:00165715 | Cervix | CC | histone methylation | 30/2311 | 141/18723 | 1.88e-03 | 1.39e-02 | 30 |
| GO:00180224 | Cervix | CC | peptidyl-lysine methylation | 28/2311 | 131/18723 | 2.43e-03 | 1.71e-02 | 28 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IWS1 | SNV | Missense_Mutation | c.1447G>A | p.Glu483Lys | p.E483K | Q96ST2 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD | |
| IWS1 | insertion | In_Frame_Ins | novel | c.1954_1955insATATACTTTCTTTCATGGTCATTGTAGCAGCTA | p.Leu652delinsHisIleLeuSerPheMetValIleValAlaAlaMet | p.L652delinsHILSFMVIVAAM | Q96ST2 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| IWS1 | SNV | Missense_Mutation | c.1900C>T | p.Arg634Trp | p.R634W | Q96ST2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| IWS1 | SNV | Missense_Mutation | c.1189N>T | p.Leu397Phe | p.L397F | Q96ST2 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| IWS1 | SNV | Missense_Mutation | novel | c.2072G>A | p.Gly691Asp | p.G691D | Q96ST2 | protein_coding | deleterious(0.02) | probably_damaging(0.972) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| IWS1 | SNV | Missense_Mutation | rs768095036 | c.247N>A | p.Glu83Lys | p.E83K | Q96ST2 | protein_coding | tolerated_low_confidence(0.11) | possibly_damaging(0.664) | TCGA-EA-A3QD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| IWS1 | SNV | Missense_Mutation | c.2389G>A | p.Asp797Asn | p.D797N | Q96ST2 | protein_coding | deleterious(0.03) | benign(0.101) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IWS1 | SNV | Missense_Mutation | c.476N>A | p.Ser159Tyr | p.S159Y | Q96ST2 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.98) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| IWS1 | insertion | Frame_Shift_Ins | novel | c.2069_2070insCCTAA | p.Gly691LeufsTer11 | p.G691Lfs*11 | Q96ST2 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
| IWS1 | SNV | Missense_Mutation | c.1691N>A | p.Ile564Asn | p.I564N | Q96ST2 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |